Wegovy in Czechia: What It Is, Who Qualifies, and How Treatment Works
Medically reviewed by MUDr. Iveta Novotná, obesitologist
Wegovy in the Czech Republic: the EMA indication and BMI criteria, the weekly pen and titration, trial results, side effects, and who actually decides.
Wegovy is what most people in Czechia mean by "the weight-loss injection", and since it reached the Czech market the question has shifted from whether it exists here to who it is actually for. This is a factual overview for residents: what the medicine is authorised to do, the criteria in its indication, how treatment is structured, and what the trials found and did not find.
What Wegovy is and who the indication covers
Wegovy contains semaglutide, a GLP-1 receptor agonist, administered as a once-weekly subcutaneous injection from a pre-filled pen. Unlike the diabetes product built on the same active substance, Wegovy is authorised in the EU specifically for weight management, as an adjunct to a reduced-calorie diet and increased physical activity, in adults with (EMA: Wegovy):
- a BMI of 30 or above (obesity), or
- a BMI of 27 to under 30 (overweight) together with at least one weight-related condition, such as high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.
The indication also extends to adolescents from 12 years of age with obesity and a body weight above 60 kg. It is a prescription-only medicine everywhere in the EU, and the phrase "adjunct to diet and exercise" is part of the authorised indication rather than a disclaimer: the medicine is not authorised as a replacement for those changes.
Availability in Czechia
Wegovy became available on prescription in Czechia in May 2025, described at the time as the first injectable legally accessible in the country to patients without diabetes for weight reduction alone, with patients paying the full price themselves (expats.cz, May 2025).
Supply of GLP-1 medicines in Czech pharmacies has fluctuated over the period since, with individual strengths moving in and out of stock. How availability is tracked is covered in GLP-1 availability in Czech pharmacies.
Dispensing works one way only. A doctor issues an eRecept, and you collect the pack at a pharmacy counter. Mail-order supply of prescription medicines is illegal in the Czech Republic, so no legitimate provider will offer to send one to your address, and any site that does is outside the law – see illegal online pharmacies in Czechia.
The weekly pen and how titration works
Treatment does not start at the full dose. According to the summary of product characteristics, the dose is raised in steps over roughly 16 weeks, the purpose being to reduce gastrointestinal side effects (EMA: Wegovy).
| Weeks of treatment | Weekly dose |
|---|---|
| Weeks 1–4 | 0.25 mg |
| Weeks 5–8 | 0.5 mg |
| Weeks 9–12 | 1 mg |
| Weeks 13–16 | 1.7 mg |
| From week 17 | 2.4 mg (maintenance) |
This schedule is a template, not a fixed timetable. If a step is poorly tolerated, the doctor can slow the titration or hold a lower dose for longer, and not every patient reaches or needs the maximum dose. The injection is given subcutaneously once a week, on the same day, independent of meals.
What the clinical trials showed
The main efficacy evidence comes from the STEP 1 trial: participants with overweight or obesity taking semaglutide 2.4 mg lost on average 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo group, with both groups also receiving lifestyle intervention (NEJM). A separate cardiovascular outcomes trial, SELECT, studied 17,604 people with established cardiovascular disease and a BMI of 27 or above, with diabetes excluded: a major adverse cardiovascular event occurred in 6.5% of those on semaglutide 2.4 mg against 8.0% on placebo over a median of roughly 42 months in the trial, a relative risk reduction of 20% (NEJM). That finding belongs to a population already diagnosed with cardiovascular disease and does not carry over to a reader who has none.
Two limitations belong next to those numbers. A trial average is not an individual forecast: response varies widely, and a meaningful share of participants lose considerably less or discontinue. And the effect depends on continued treatment – in the SURMOUNT-4 withdrawal trial, run with a different active substance in the same broad class, participants who stopped regained a substantial proportion of the weight lost (JAMA). That is why obesity is treated as a chronic, relapsing condition, and why the end of treatment should be planned from the start.
Who decides, and how the pathway works here
Nothing above tells you whether treatment is appropriate for you, and that is deliberate. Eligibility rests on a clinical assessment: BMI, weight-related conditions, your medical history, medicines you already take, previous attempts and your goals. The doctor's judgement is the deciding factor, and a doctor can and does conclude that pharmacological treatment is not suitable for a given patient. Our BMI calculator gives you a number to bring to that conversation, nothing more.
You do not need a registered Czech GP to be assessed, which matters here: more than 554,000 people in Czechia are not registered with a GP, about 65% of them foreign nationals – roughly 360,000 people (expats.cz). The route without one is described in obesity treatment in Czechia without a GP. With GoOn you fill in an online questionnaire and then have a video consultation with a licensed Czech doctor in English, at no language surcharge, where Prague clinics commonly add a few hundred crowns for an English-speaking appointment (expats.cz). If the doctor concludes treatment is appropriate, they issue a native Czech eRecept and you collect it at any Czech pharmacy. Discuss your options with a doctor online.
Side effects and contraindications
The most common adverse effects are gastrointestinal: nausea, vomiting, diarrhoea and constipation, typically clustered around the periods when the dose is increased (EMA: Wegovy). Less common but more serious effects include pancreatitis and gallbladder problems. The medicine must not be used in case of hypersensitivity to the active substance, and it is not intended for use during pregnancy or breastfeeding; caution applies, among others, to patients with a history of pancreatic disease. Combined with insulin or sulfonylureas, the risk of hypoglycaemia increases. The complete list of contraindications, warnings and interactions is in the summary of product characteristics (EMA product information). A doctor always weighs these benefits and risks for the individual patient and may decide against treatment.
Cost: self-pay in Czechia, for everyone
Pharmacotherapy for obesity is not reimbursed from Czech public health insurance, so patients pay for the medicine themselves. This is not a foreigner-specific rule and there is no separate price for non-Czechs: the policy covers what public insurance covers, and these medicines are not publicly reimbursed for anyone. Some insurers contribute modest amounts from their prevention funds. The pharmacy price depends on the product and the dose, so the monthly total shifts as the dose changes. Costs are broken down in what weight-loss treatment costs in Czechia, reimbursement rules in Czech health insurance and weight-loss medication.
Practical notes for foreigners living in Czechia
A Czech eRecept can be issued to you without a Czech insurance number, since the patient identifier can be your name and date of birth. The catch is at the counter: the pharmacy's routine lookup by ID card does not work for non-residents, so you must bring the prescription code itself, received by SMS or printed out. Cross-border acceptance of foreign e-prescriptions in Czechia is also only partial, because only some pharmacies take part in the scheme (ePreskripce, in Czech) – one reason a prescription issued natively in the Czech system is more dependable when you live here. See our guide to the Czech eRecept, and if you moved here mid-treatment, continuing GLP-1 treatment after moving to Czechia.
Frequently asked questions
Who qualifies for Wegovy in the Czech Republic?
The EU indication covers adults with a BMI of 30 or above, or a BMI of 27 to under 30 with at least one weight-related condition such as high blood pressure or sleep apnoea, plus adolescents from 12 with obesity and weight above 60 kg (EMA). Meeting the criteria on paper is not the same as being suitable: a doctor assesses your full history and may decline treatment.
How does prescribing work in Czechia if I have no Czech GP?
You do not need a registered GP for an assessment, which is relevant given that roughly 360,000 foreigners here have none (expats.cz). A licensed Czech doctor assesses you, decides whether treatment is appropriate, and issues an eRecept only if it is. The medicine is then dispensed at a pharmacy, never posted.
Does Czech insurance cover Wegovy?
No. Weight-management medicines are not reimbursed from Czech public health insurance, so the patient pays the pharmacy price. The same applies to Czech citizens and foreign residents alike; some insurers offer small contributions from prevention funds.
How long does treatment last?
There is no fixed course. Obesity is treated as a chronic condition, and withdrawal evidence shows that a large part of lost weight tends to return after treatment stops (JAMA). Duration, dose and what follows are decided with your doctor and reviewed as treatment progresses.